Callahan Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
VCM
VPM
Callahan Advisors's BMY Position: Q1 2026 in Review
Callahan Advisors increased its Bristol-Myers Squibb (BMY) stake by 6.4% in Q1 2026, buying an estimated $46.9K and bringing the position to 13,291 shares worth $806K. The position accounts for 0.07% of the portfolio, ranked #122.
Callahan Advisors first reported a position in BMY in Q3 2020 and has held it in 22 quarters since. The position peaked at $7.11M in Q4 2022. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Callahan Advisors held 13,291 shares of Bristol-Myers Squibb worth $806K as of Q1 2026.
- Callahan Advisors bought 804 Bristol-Myers Squibb shares in Q1 2026, an estimated $46.9K.
- Bristol-Myers Squibb made up 0.07% of Callahan Advisors's portfolio in Q1 2026, its #122 holding.
- Callahan Advisors first reported a position in Bristol-Myers Squibb in Q3 2020 and has held it in 22 quarters since.
- Callahan Advisors's Bristol-Myers Squibb position peaked at $7.11M in Q4 2022.
- 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Callahan Advisors's 13F filing for Q1 2026, filed 12 May 2026.